IRIS
ARDIZZONI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.083
AS - Asia 1.717
EU - Europa 1.266
SA - Sud America 209
AF - Africa 110
Continente sconosciuto - Info sul continente non disponibili 47
OC - Oceania 7
Totale 5.439
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.031
CN - Cina 576
SG - Singapore 552
FI - Finlandia 268
VN - Vietnam 260
IE - Irlanda 197
SE - Svezia 197
IT - Italia 196
BR - Brasile 156
DE - Germania 140
HK - Hong Kong 108
TR - Turchia 69
FR - Francia 66
ZA - Sudafrica 64
NL - Olanda 48
GB - Regno Unito 47
BD - Bangladesh 40
CA - Canada 31
IN - India 28
UA - Ucraina 28
CI - Costa d'Avorio 26
AR - Argentina 21
PL - Polonia 20
RU - Federazione Russa 13
MX - Messico 12
JP - Giappone 10
PK - Pakistan 10
EC - Ecuador 8
ES - Italia 8
PH - Filippine 8
BE - Belgio 7
MA - Marocco 7
CO - Colombia 6
CZ - Repubblica Ceca 6
IQ - Iraq 6
JO - Giordania 6
LT - Lituania 6
AT - Austria 5
AU - Australia 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
VE - Venezuela 5
CL - Cile 4
ID - Indonesia 4
MY - Malesia 4
PY - Paraguay 4
EG - Egitto 3
KR - Corea 3
NP - Nepal 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
BB - Barbados 2
BY - Bielorussia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
IR - Iran 2
KE - Kenya 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
OM - Oman 2
PE - Perù 2
SI - Slovenia 2
SN - Senegal 2
TH - Thailandia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
TJ - Tagikistan 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.393
Salva come PNG Salva come JPEG
Città #
Singapore 308
Ashburn 274
Chandler 260
Dublin 197
San Jose 170
Beijing 143
Dallas 138
Santa Clara 123
Hong Kong 101
Ho Chi Minh City 82
New York 77
Parma 69
Nanjing 66
Dearborn 62
Johannesburg 60
Council Bluffs 59
Izmir 57
Munich 56
Shanghai 54
Boardman 53
Hanoi 53
Los Angeles 45
Ann Arbor 39
Jacksonville 36
Princeton 35
Lauterbourg 33
Abidjan 26
San Mateo 26
Bremen 25
Wilmington 24
Kunming 22
Jinan 20
Turku 20
Helsinki 19
São Paulo 19
Tianjin 18
Shenyang 17
Buffalo 16
Denver 16
Frankfurt am Main 16
Nanchang 15
Hefei 14
Warsaw 14
Da Nang 13
Haiphong 12
Jiaxing 12
Seattle 12
Hebei 11
Toronto 11
Columbus 10
Marseille 9
Guangzhou 8
Hangzhou 8
London 8
Milan 8
Rio Saliceto 8
Tokyo 8
Brussels 7
Chicago 7
Leawood 7
Montreal 7
Phoenix 7
Poplar 7
Zhengzhou 7
Biên Hòa 6
Brooklyn 6
Chennai 6
Haikou 6
Houston 6
Leipzig 6
Norwalk 6
Pune 6
Amman 5
Bexley 5
Hải Dương 5
Moscow 5
New Delhi 5
Ottawa 5
Rio de Janeiro 5
Rome 5
San Francisco 5
The Dalles 5
Woodbridge 5
Amsterdam 4
Belo Horizonte 4
Changsha 4
Chengdu 4
City of London 4
Des Moines 4
Fuzhou 4
Istanbul 4
Memphis 4
Mexico City 4
Nuremberg 4
Quito 4
Stockholm 4
Sydney 4
Taizhou 4
Wroclaw 4
Ankara 3
Totale 3.334
Salva come PNG Salva come JPEG
Nome #
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 209
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 196
Characterization of gefitinib uptake in NSCLC cell lines 194
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 192
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 187
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 186
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 185
Histological subtype analysis of colon cancer: a population-based study. Different sides and different diseases. 182
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 180
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 175
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 173
Cancer stem cells related marker CD44 and Notch activation in metastatic colon cancer patients 172
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 168
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer 167
Neoplasie del polmone in Neoplasie del Distretto Toracico 166
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 160
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 158
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 158
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 157
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 151
Notch Activation Modulates Bevacizumab Activity by CD44 Positive Cancer Stem Cells in Advanced Colon Cancer 151
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 149
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 149
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 147
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 145
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 141
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 136
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 136
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 121
Effect of dual PI3K and FAK inhibition in squamous lung carcinoma with reduced PTEN level 119
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 116
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 112
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 106
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 104
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 91
Totale 5.439
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022119 0 1 1 12 2 0 5 15 9 9 8 57
2022/2023805 70 113 57 63 73 102 5 54 239 0 21 8
2023/2024279 12 21 6 9 24 92 20 18 11 6 14 46
2024/2025953 37 37 51 67 116 92 24 33 144 69 97 186
2025/20261.993 227 175 199 212 308 130 159 78 262 148 62 33
2026/2027113 32 81 0 0 0 0 0 0 0 0 0 0
Totale 5.439